Interleukin Genetics, Inc. Announces Conference Call to Discuss Third Quarter 2014 Results

WALTHAM, Mass.--()--Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and Webcast on Friday, November 14, 2014, at 8:30 a.m. (ET) to provide a corporate update and discuss the Company’s third quarter results.

To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 (international). The live webcast will be available at the Investors section of the Company’s website,

About Interleukin Genetics, Inc.

Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets a line of genetic tests under the Inherent Health® and PerioPredict™ brands. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics’ flagship products include its proprietary genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit


Argot Partners
David Pitts, 212-600-1902
Argot Partners
Susan Kim, 212-600-1902

Interleukin Genetics, Inc.